SCHEMBL1630199

SCHEMBL1630199

CCn1nc(-c2cn(C(C)C)c3cc([N+](=O)[O-])ccc23)cc1C#N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 6/20 0.39
PGR P06401 6/20 0.39
NR3C2 P08235 6/20 0.39
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
MAPT P10636 4/20 0.37
AR P10275 5/20 0.35
CYP1A2 P05177 1/20 0.35
LMNA P02545 2/20 0.33
ELANE P08246 1/20 0.32
CNR1 P21554 1/20 0.32
ACHE P22303 1/20 0.32
CNR2 P34972 1/20 0.32
GAA P10253 1/20 0.32
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31
PIK3CD O00329 1/20 0.31
PIK3CA P42336 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1630524 0.92 NR3C1 (0.35) NR3C1PGRNR3C2MEN1KMT2A
SCHEMBL1629078 0.82 MEN1 (0.37) NR3C1PGRNR3C2MEN1KMT2A
SCHEMBL1630701 0.79 PGR (0.60) NR3C1PGRNR3C2MEN1KMT2A
SCHEMBL1631052 0.77 CA12 (0.43) NR3C1PGRNR3C2MEN1KMT2A
SCHEMBL1630381 0.75 MAPT (0.39) NR3C1PGRNR3C2MEN1KMT2A
SCHEMBL28918792 0.74 MEN1 (0.47) NR3C1PGRNR3C2MEN1KMT2A
SCHEMBL1629260 0.73 NR3C1 (0.52) NR3C1PGRNR3C2MEN1KMT2A
SCHEMBL1630690 0.73 NR3C1 (0.43) NR3C1PGRNR3C2MEN1KMT2A
SCHEMBL1631691 0.72 MEN1 (0.40) NR3C1PGRNR3C2MEN1KMT2A
SCHEMBL1630952 0.71 PGR (0.50) NR3C1PGRNR3C2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979314-B1 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS LILLY CO ELI (US) 2013-01-09 EP disclosed
CN-101374808-B Indole sulfonamide modulators of progesterone receptors LILLY CO ELI 2011-05-25 CN disclosed
US-7932284-B2 Indole sulfonamide modulators of progesterone receptors ELI LILLY AND COMPANY (US) 2011-04-26 US disclosed
US-20090069400-A1 Indole Sulfonamide Modulators of Progesterone Receptors ELI LILLY AND COMPANY 2009-03-12 US disclosed
CN-101374808-A Indole sulfonamide modulators of progesterone receptors LILLY CO ELI (US) 2009-02-25 CN disclosed
EP-1979314-A2 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS Eli Lilly & Company (US) 2008-10-15 EP disclosed
WO-2007087488-A9 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS LILLY CO ELI (US) 2008-08-28 WO disclosed
WO-2007087488-A2 INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS ELI LILLY AND COMPANY (US) 2007-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069400-A1 Indole Sulfonamide Modulators of Progesterone Receptors PGR, NPSR1, PRLHR NR3C1 63/4885PGR 1/4885NR3C2 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.